Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe

Chloe J Bright, Mike M Hawkins, David L Winter, Daniela Alessi, Rodrigue S Allodji, Francesca Bagnasco, Edit Bárdi, Andrea Bautz, Julianne Byrne, Elizabeth A M Feijen, Miranda M Fidler, Stanislaw Garwicz, Desiree Grabow, Thorgerdur Gudmundsdottir, Joyeeta Guha, Nadia Haddy, Momcilo Jankovic, Peter Kaatsch, Melanie Kaiser, Claudia E Kuehni, Helena Linge, Hilde Øfstaas, Cecile M Ronckers, Roderick Skinner, Jop C Teepen, Monica Terenziani, Giao Vu-Bezin, Finn Wesenberg, Thomas Wiebe, Carlotta Sacerdote, Zsuzsanna Jakab, Riccardo Haupt, Päivi Lähteenmäki, Lorna Zadravec Zaletel, Rahel Kuonen, Jeanette F Winther, Florent de Vathaire, Leontien C Kremer, Lars Hjorth, Raoul C Reulen, PanCareSurFup Consortium, Chloe J Bright, Mike M Hawkins, David L Winter, Daniela Alessi, Rodrigue S Allodji, Francesca Bagnasco, Edit Bárdi, Andrea Bautz, Julianne Byrne, Elizabeth A M Feijen, Miranda M Fidler, Stanislaw Garwicz, Desiree Grabow, Thorgerdur Gudmundsdottir, Joyeeta Guha, Nadia Haddy, Momcilo Jankovic, Peter Kaatsch, Melanie Kaiser, Claudia E Kuehni, Helena Linge, Hilde Øfstaas, Cecile M Ronckers, Roderick Skinner, Jop C Teepen, Monica Terenziani, Giao Vu-Bezin, Finn Wesenberg, Thomas Wiebe, Carlotta Sacerdote, Zsuzsanna Jakab, Riccardo Haupt, Päivi Lähteenmäki, Lorna Zadravec Zaletel, Rahel Kuonen, Jeanette F Winther, Florent de Vathaire, Leontien C Kremer, Lars Hjorth, Raoul C Reulen, PanCareSurFup Consortium

Abstract

Background: Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are unknown. We quantified the risk of STS histological subtypes after specific types of childhood cancer.

Methods: We pooled data from 13 European cohorts, yielding a cohort of 69 460 five-year survivors of childhood cancer. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated.

Results: Overall, 301 STS developed compared with 19 expected (SIR = 15.7, 95% confidence interval [CI] = 14.0 to 17.6). The highest standardized incidence ratios were for malignant peripheral nerve sheath tumors (MPNST; SIR = 40.6, 95% CI = 29.6 to 54.3), leiomyosarcomas (SIR = 29.9, 95% CI = 23.7 to 37.2), and fibromatous neoplasms (SIR = 12.3, 95% CI = 9.3 to 16.0). SIRs for MPNST were highest following central nervous system tumors (SIR = 80.5, 95% CI = 48.4 to 125.7), Hodgkin lymphoma (SIR = 81.3, 95% CI = 35.1 to 160.1), and Wilms tumor (SIR = 76.0, 95% CI = 27.9 to 165.4). Standardized incidence ratios for leiomyosarcoma were highest following retinoblastoma (SIR = 342.9, 95% CI = 245.0 to 466.9) and Wilms tumor (SIR = 74.2, 95% CI = 37.1 to 132.8). AERs for all STS subtypes were generally low at all years from diagnosis (AER < 1 per 10 000 person-years), except for leiomyosarcoma following retinoblastoma, for which the AER reached 52.7 (95% CI = 20.0 to 85.5) per 10 000 person-years among patients who had survived at least 45 years from diagnosis of retinoblastoma.

Conclusions: For the first time, we provide risk estimates of specific STS subtypes following childhood cancers and give evidence that risks of MPNSTs, leiomyosarcomas, and fibromatous neoplasms are particularly increased. While the multiplicative excess risks relative to the general population are substantial, the absolute excess risk of developing any STS subtype is low, except for leiomyosarcoma after retinoblastoma. These results are likely to be informative for both survivors and health care providers.

Figures

Figure 1.
Figure 1.
Cumulative incidence of all subsequent primary soft-tissue sarcomas (A), leiomyosarcomas (B), malignant peripheral nerve sheath tumors (C), and fibromatous neoplasms (D) in five-year survivors of childhood cancer, by years from diagnosis. Cumulative incidence was calculated treating death as a competing risk using the stcompet command in Stata. CNS = central nervous system; HL = Hodgkin lymphoma; MPNST = malignant peripheral nerve sheath tumor; Rb = retinoblastoma; STS = soft tissue sarcoma.

References

    1. Gatta G, Botta L, Rossi S, et al. . Childhood cancer survival in Europe 1999–2007: Results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15(1):35–47.
    1. Hjorth L, Haupt R, Skinner R, et al. . Survivorship after childhood cancer: PanCare: A European Network to promote optimal long-term care. Eur J Cancer. 2015;51(10):1203–1211.
    1. Reulen RC, Frobisher C, Winter DL, et al. . Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA. 2011;305(22):2311–2319.
    1. Olsen JH, Moller T, Anderson H, et al. . Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries. J Natl Cancer Inst. 2009;101(11):806–813.
    1. Friedman DL, Whitton J, Leisenring W, et al. . Subsequent neoplasms in 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102(14):1083–1095.
    1. Inskip PD, Curtis RE. New malignancies following childhood cancer in the United States, 1973-2002. Int J Cancer. 2007;121(10):2233–2240.
    1. Cardous-Ubbink MC, Heinen RC, Bakker PJ, et al. . Risk of second malignancies in long-term survivors of childhood cancer. Eur J Cancer. 2007;43(2):351–362.
    1. Wilson CL, Cohn RJ, Johnston KA, et al. . Late mortality and second cancers in an Australian cohort of childhood cancer survivors. Med J Aust. 2010;193(5):258–261.
    1. Henderson TO, Whitton J, Stovall M, et al. . Secondary sarcomas in childhood cancer survivors: A report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2007;99(4):300–308.
    1. Jenkinson HC, Winter DL, Marsden HB, et al. . A study of soft tissue sarcomas after childhood cancer in Britain. Br J Cancer. 2007;97(5):695–699.
    1. Menu-Branthomme A, Rubino C, Shamsaldin A, et al. . Radiation dose, chemotherapy and risk of soft tissue sarcoma after solid tumours during childhood. Int J Cancer. 2004;110(1):87–93.
    1. Henderson TO, Rajaraman P, Stovall M, et al. . Risk factors associated with secondary sarcomas in childhood cancer survivors: A report from the childhood cancer survivor study. Int J Radiat Oncol Biol Phys. 2012;84(1):224–230.
    1. Berrington de Gonzalez A, Kutsenko A, Rajaraman P. Sarcoma risk after radiation exposure. Clin Sarcoma Res. 2012;2:18–18.
    1. Kleinerman RA, Schonfeld SJ, Tucker MA. Sarcomas in hereditary retinoblastoma. Clin Sarcoma Res. 2012;2(1):15.
    1. Kleinerman RA, Tucker MA, Abramson DH, et al. . Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst. 2007;99(1):24–31.
    1. Wong JR, Morton LM, Tucker MA, et al. . Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol. 2014;32(29):3284–3290.
    1. Marees T, Moll AC, Imhof SM, et al. . Risk of second malignancies in survivors of retinoblastoma: More than 40 years of follow-up. J Natl Cancer Inst. 2008;100(24):1771–1779.
    1. Wong FL, Boice JD Jr., Abramson DH, et al. . Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278(15):1262–1267.
    1. Steliarova-Foucher E, Stiller C, Lacour B, et al. . International Classification of Childhood Cancer, third edition. Cancer. 2005;103(7):1457–1467.
    1. Ferlay J. IARC/IARC Cancer Registry Tools (IARCcrgTools). 2.05 ed. Lyon, France: Descriptive Epidemiology Group, International Agency fo Research on Cancer; 2008.
    1. Barr RD, Holowaty EJ, Birch JM. Classification schemes for tumors diagnosed in adolescents and young adults. Cancer. 2006;106(7):1425–1430.
    1. Office of National Statistics. Cancer Statistics Registrations - Series MB1. London: Stationary Office; 2006.
    1. Statistics Finland. Cancer Registrations 2011. Finish Cancer Registry. Cancer registrations 2015.
    1. Dickman PW, Sloggett A, Hills M, et al. . Regression models for relative survival. Stat Med. 2004;23(1):51–64.
    1. Covillo V, Bogges M. Cumulative incidence estimation in the presence of competing risks. Stata J. 2004:103–112.
    1. Esteve J, Benhamou E, Raymon L. Statistical Methods in Cancer Research. Volume IV: Descriptive Epidemiology. Lyon: International Agency for Research on Cancer (WHO; ); 1994.
    1. Ederer F, Heiser H. Instructions to IBM 650 Programmers in Processing Survival Computations Methodological note no. 10. Bethesda: National Cancer Institute; 1959.
    1. MacCarthy A, Bayne AM, Brownbill PA, et al. . Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004. Br J Cancer. 2013;108(12):2455–2463.
    1. Sharif S, Ferner R, Birch JM, et al. . Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: Substantial risks after radiotherapy. J Clin Oncol. 2006;24(16):2570–2575.
    1. Kahn J, Gillespie A, Tsokos M, et al. . Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol. 2014;4:324.
    1. Ducatman BS, Scheithauer BW, Piepgras DG, et al. . Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57(10):2006–2021.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe